Novo Nordisk says Wegovy shows greater weight loss than Eli Lilly's rival pill
A cross-trial comparison shows Novo's oral semaglutide produced 3.2 percentage points more weight loss than Foundayo, with Eli Lilly's drug seeing significantly higher dropout rates due to side effects. [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients
Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.Read more... [...]